CytoImmune Therapeutics is at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials. In addition, the Company is now offering cell therapy development and clinical manufacturing services to both biotechnology companies and academia. CytoImmune's cutting edge clinical cell manufacturing facility in Toa Baja, Puerto Rico, is custom built to support the development and commercialization of emergent T cell or NK cell therapies. At CytoImmune, the Company is fostering collaborations that drive the future of cell therapy and improve the lives of cancer patients.